How many insider trades does FilingIQ track for INM?

FilingIQ tracks 29 Form 4 insider transactions for INM (InMed Pharmaceuticals Inc.), covering filings from Sep 28, 2021 onwards. 3 of those were filed in the last 90 days.

Are INM insiders net buyers or net sellers?

Across the full Form 4 history for INM, 14 transactions (48%) were open-market purchases and 1 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INM insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INM in?

InMed Pharmaceuticals Inc. (INM) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $2.04M.

INM insider trading

NasdaqCM Healthcare

InMed Pharmaceuticals Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

48% / 3%

Market cap

$2.04M

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Company website: www.inmedpharma.com

INM insider activity at a glance

FilingIQ has scored 29 insider transactions for INM since Sep 28, 2021. The most recent filing in our index is dated May 19, 2026.

Across the full history, 14 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INM insider trades is 58.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INM trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,265

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 195

Guardant Health, Inc.

ADPT 184

Adaptive Biotechnologies Corp

BMY 182

BRISTOL MYERS SQUIBB CO

VTRS 165

Viatris Inc

ALNY 153

ALNYLAM PHARMACEUTICALS, INC.

Frequently asked

How many insider trades does FilingIQ track for INM?: FilingIQ tracks 29 Form 4 insider transactions for INM (InMed Pharmaceuticals Inc.), covering filings from Sep 28, 2021 onwards. 3 of those were filed in the last 90 days.
Are INM insiders net buyers or net sellers?: Across the full Form 4 history for INM, 14 transactions (48%) were open-market purchases and 1 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INM insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INM in?: InMed Pharmaceuticals Inc. (INM) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $2.04M.

Methodology & sources

Every INM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.